rdf:type |
|
lifeskim:mentions |
umls-concept:C0001128,
umls-concept:C0017168,
umls-concept:C0030705,
umls-concept:C0039225,
umls-concept:C0081876,
umls-concept:C0262926,
umls-concept:C0267055,
umls-concept:C0332119,
umls-concept:C0376315,
umls-concept:C0439185,
umls-concept:C0442027,
umls-concept:C0993609,
umls-concept:C1709366
|
pubmed:issue |
2
|
pubmed:dateCreated |
2007-6-26
|
pubmed:abstractText |
To demonstrate the pharmacodynamic comparability between oral 40 mg pantoprazole delayed-release granules and tablets.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0269-2813
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
26
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
249-56
|
pubmed:meshHeading |
pubmed-meshheading:17593070-2-Pyridinylmethylsulfinylbenzimidazoles,
pubmed-meshheading:17593070-Administration, Oral,
pubmed-meshheading:17593070-Adolescent,
pubmed-meshheading:17593070-Adult,
pubmed-meshheading:17593070-Aged,
pubmed-meshheading:17593070-Analysis of Variance,
pubmed-meshheading:17593070-Anti-Ulcer Agents,
pubmed-meshheading:17593070-Cross-Over Studies,
pubmed-meshheading:17593070-Esophagitis,
pubmed-meshheading:17593070-Female,
pubmed-meshheading:17593070-Gastric Acid,
pubmed-meshheading:17593070-Gastroesophageal Reflux,
pubmed-meshheading:17593070-Humans,
pubmed-meshheading:17593070-Hydrogen-Ion Concentration,
pubmed-meshheading:17593070-Male,
pubmed-meshheading:17593070-Middle Aged
|
pubmed:year |
2007
|
pubmed:articleTitle |
Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis.
|
pubmed:affiliation |
Clinical Applications Lab., Inc., San Diego, CA, USA.
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|